<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DICUMAROL</span><br/>(dye-koo'ma-role)<br/><span class="topboxtradename">Bishydroxycoumarin<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and oral anticoagulants</span><br/><b>Prototype: </b>Warfarin<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting coumarin derivative.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Interferes with blood clotting by depressing hepatic synthesis of vitamin K-dependent coagulation factors: II, VII, IX, X.</p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis and treatment of DVT.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hemorrhagic tendencies: hemophilia, thrombocytopenia, leukemia; open wounds or ulcers; renal or hepatic impairment, vitamin
         C or K deficiency; severe hypertension; subacute bacterial endocarditis; visceral carcinoma. Safe use during pregnancy (category
         D), lactation, or in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Active tuberculosis, major surgery, indwelling catheters.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Anticoagulant</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200300 mg on day 1, then 25200 mg/d based on PT time<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to enhance drug absorption. Frequent dosage adjustment may be necessary during first 12 wk of therapy
            because drug absorption is so variable.
         </li>
<li>Give consistently with respect to time of day.</li>
<li>Store in tightly closed container at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span> Diarrhea, flatulence, nausea, vomiting, anorexia, abdominal cramping. <span class="typehead">Urogenital:</span>  Hematuria, priapism. <span class="typehead">Hematologic:</span> Leukopenia, agranulocytosis, hemorrhage. <span class="typehead"> Skin:</span> Unusual hair loss, urticaria, dermatitis. <span class="typehead">Other:</span> Hypersensitivity, fever. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>  See <b>warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly and incompletely absorbed from GI tract. <span class="typehead">Peak:</span> 14 d. <span class="typehead">Duration:</span> 210 d. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 7085% excreted in urine, 1530% in feces. <span class="typehead">Half-Life:</span> 12 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Check PT and INR daily during period of dosage adjustment; obtain dose order following results. Check PT and INR
            in patient on controlled maintenance dose semiweekly, weekly for 34 wk, then at 1- to 4-wk intervals, depending on stability
            of patient's response.
         </li>
<li>Draw blood for PT and INR at least 5 h after an IV bolus dose of heparin or 24 h following a full therapeutic SC heparin dose.
            Continuous IV infusion or low doses of heparin SC usually do not cause a significant increase in PT; therefore, blood can
            be drawn at any time.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Inform physician of any other medication being taken, including OTC drugs.</li>
<li>Do not add or discontinue any medication without approval of physician or pharmacist.</li>
<li>Report immediately to physician any unexplained bleeding, easy bruising, or prolonged bleeding time.</li>
<li>Tell all doctors and dentists before care that you are on anticoagulant therapy.</li>
<li>Avoid unusual changes in vitamin intake, diet, or life-style without consulting physician. Also notify physician of any changes
            in health status. Illness may increase anticoagulant requirement.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>